Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorFirst Affiliated Hospital of Guangxi Medical University

About this trial

The purpose of this study was to investigate the role of immunonutrion compared with standard nutrition in reducing oral mucositis in patients with locally advanced nasopharyngeal carcinoma.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Eastern Cooperative Oncology Group (ECOG) performance status 0-1;

Age 18-70 years old, male or non-pregnant women;

Pathologically confirmed non-keratinizing carcinoma of the nasopharynx (differentiated or undifferentiated,WHO type II or III);

Newly diagnosed stage III-IVa (8th AJCC/UICC stage) NPC patients;

Disqualifiers

History of investigational Oral Impact®/ENSURE® use within the month prior to enrollment;

Known allergy or intolerance to any component of investigational Oral Impact®/ENSURE® or related chemotherapy drugs;

Poor glycemic control in patients with diabetes;

Patients with autoimmune diseases;

Trial design

Design model

Parallel

Treatments tested in this trial

  • Enteral immunonutrition

    Dietary supplement

    Enteral immunonutrition (Oral Impact®, Nestle), 250ml/ bottle, 2 bottles per day, from 5 days before radiotherapy to the end of radiotherapy.

  • Standard enteral nutrition

    Dietary supplement

    Isocaloric standard enteral nutrition formula (ENSURE®), 250 mL per administration, 3 times per day. Preparation of the 250 mL dose involves adding 200 mL of potable water to a cup and slowly stirring in 52.7 g of ENSURE powder (approximately 6 scoops).

Treatment groups

190 Participants
are divided into 2 treatment groups
Group A: Immunonutrition GroupExperimental treatment 1 intervention
Group B: Control GroupActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

The incidence of severe oral mucositis

Incidence of grade 3-4 oral mucositis

Time frame
7 weeks

Secondary outcomes

1

The latency period of severe oral mucositis

Total duration from the start of radiotherapy to the severe oral mucositis

Time frame
7 weeks
2

The duration period of severe oral mucositis

The number of days of severe oral mucositis during the oral mucositis observation period

Time frame
7 weeks
3

Assessment of immune state

T-lymphocyte subsets

Time frame
4 months
4

Serum hypersensitive C-reactive protein (hsCRP) level

Change in high sensitivity C-reactive protein from baseline to end of radiotherapy

Time frame
4 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

First Affiliated Hospital of Guangxi Medical University

Lead sponsor

Guangdong Provincial People's Hospital

Collaborator

Zhejiang Cancer Hospital

Collaborator

Zhejiang Provincial People's Hospital

Collaborator

Fujian Cancer Hospital

Collaborator

Fujian Provincial Hospital

Collaborator

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Collaborator

The First Affiliated Hospital of Nanchang University

Collaborator

Second Affiliated Hospital of Nanchang University

Collaborator

Affiliated Cancer Hospital & Institute of Guangzhou Medical University

Collaborator

Qingdao Central Hospital

Collaborator

Huizhou Municipal Central Hospital

Collaborator

Haikou People's Hospital

Collaborator

The Second Affiliated Hospital of Hainan Medical University

Collaborator

Zhejiang Provincial Tongde Hospital

Collaborator

Guilin Medical University, China

Collaborator

Liuzhou Workers' Hospital

Collaborator

Wuzhou Red Cross Hospital

Collaborator

Red Cross Hospital of Yulin City

Collaborator

First People's Hospital of Yulin

Collaborator

Hainan Cancer Hospital

Collaborator